MA43745A - Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer - Google Patents
Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancerInfo
- Publication number
- MA43745A MA43745A MA043745A MA43745A MA43745A MA 43745 A MA43745 A MA 43745A MA 043745 A MA043745 A MA 043745A MA 43745 A MA43745 A MA 43745A MA 43745 A MA43745 A MA 43745A
- Authority
- MA
- Morocco
- Prior art keywords
- dihydropyrrolo
- pyrazole
- cancer
- treatment
- carbonitrile derivatives
- Prior art date
Links
- SMJKYKNYWBAFPU-UHFFFAOYSA-N 4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical class N1N=CC2=C1CN(C2)C#N SMJKYKNYWBAFPU-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1604638.5A GB201604638D0 (en) | 2016-03-18 | 2016-03-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43745A true MA43745A (fr) | 2018-11-28 |
Family
ID=55968542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043745A MA43745A (fr) | 2016-03-18 | 2017-03-17 | Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11306096B2 (https=) |
| EP (1) | EP3430012B1 (https=) |
| JP (1) | JP6959248B2 (https=) |
| CN (1) | CN108473502B (https=) |
| GB (1) | GB201604638D0 (https=) |
| MA (1) | MA43745A (https=) |
| WO (1) | WO2017158381A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2976741C (en) | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) * | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| KR102709679B1 (ko) | 2018-04-25 | 2024-09-26 | 바이엘 악티엔게젤샤프트 | 살충제로서의 신규 헤테로아릴-트리아졸 및 헤테로아릴-테트라졸 화합물 |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| JP2023520727A (ja) | 2020-04-08 | 2023-05-18 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤として活性を有するｎ－シアノピロリジン |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| IL298526A (en) | 2020-05-28 | 2023-01-01 | Mission Therapeutics Ltd | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
| US20230303547A1 (en) | 2020-06-04 | 2023-09-28 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| DK4161929T3 (da) | 2020-06-08 | 2025-08-18 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| AU2010341537A1 (en) | 2009-12-22 | 2012-08-09 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases |
| WO2012040527A2 (en) | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| WO2012174199A1 (en) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Imidazopyridin-2-one derivatives |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP5833764B2 (ja) * | 2011-09-30 | 2015-12-16 | 山東軒竹医薬科技有限公司 | 縮合環を有するオキサゾリドン（ｏｘａｚｏｌｉｄｏｎｅ）類の抗菌物質 |
| EP2938610A2 (en) * | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| SG11201608943VA (en) | 2014-04-30 | 2016-11-29 | Univ Columbia | Substituted 4-phenylpiperidines, their preparaiton and use |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CA2976741C (en) | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
-
2016
- 2016-03-18 GB GBGB1604638.5A patent/GB201604638D0/en not_active Ceased
-
2017
- 2017-03-17 JP JP2018548677A patent/JP6959248B2/ja active Active
- 2017-03-17 WO PCT/GB2017/050755 patent/WO2017158381A1/en not_active Ceased
- 2017-03-17 US US16/080,229 patent/US11306096B2/en active Active
- 2017-03-17 CN CN201780007893.4A patent/CN108473502B/zh active Active
- 2017-03-17 EP EP17713402.0A patent/EP3430012B1/en active Active
- 2017-03-17 MA MA043745A patent/MA43745A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11306096B2 (en) | 2022-04-19 |
| US20210221813A1 (en) | 2021-07-22 |
| EP3430012A1 (en) | 2019-01-23 |
| CN108473502B (zh) | 2022-04-26 |
| JP2019508462A (ja) | 2019-03-28 |
| JP6959248B2 (ja) | 2021-11-02 |
| WO2017158381A1 (en) | 2017-09-21 |
| CN108473502A (zh) | 2018-08-31 |
| GB201604638D0 (en) | 2016-05-04 |
| EP3430012B1 (en) | 2021-06-16 |
| WO2017158381A8 (en) | 2018-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43745A (fr) | Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| EP3781564C0 (en) | PYRIDAZINE DERIVATIVES FOR TREATING CANCER | |
| IL268737A (en) | Processes for the preparation of benzodiapine derivatives | |
| ZA202103099B (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
| HUE053643T2 (hu) | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| IL287168A (en) | Kit of pyrrolotriazine derivatives for the treatment of diseases mediated by pdgfra | |
| EP3380475A4 (en) | OCTAHYDROPYRROLO [3,4-C | |
| EP3436014A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA | |
| EP3454896A4 (en) | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | |
| SI3353177T1 (sl) | Triciklični heterocikli za zdravljenje raka | |
| PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
| EP3947460A4 (en) | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER | |
| EP3423048A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF EGG CANCER | |
| EP3346989A4 (en) | STABLE LIPOSOMAL FORMULATIONS OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF CANCER | |
| EP3471774A4 (en) | PORPHYRINE COMPOUNDS AND COMPOSITIONS FOR TREATING CANCER | |
| MA42988A (fr) | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide | |
| MX2017009597A (es) | Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100. | |
| PL3277687T3 (pl) | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów | |
| MA54223A (fr) | Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one servant d'inhibiteurs de hpk1 pour le traitement du cancer | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
| HK40049719A (en) | Dosing regimen for the treatment of pi3k related disorders |